Gini Fleming to Carcinoma
This is a "connection" page, showing publications Gini Fleming has written about Carcinoma.
Connection Strength
1.210
-
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117(1):37-40.
Score: 0.282
-
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007 Jul 10; 25(20):2983-90.
Score: 0.236
-
Rare uterine cancers. Lancet Oncol. 2005 Dec; 6(12):961-71.
Score: 0.211
-
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004 Aug; 15(8):1173-8.
Score: 0.192
-
Systemic therapy for advanced or recurrent endometrial carcinoma. Curr Oncol Rep. 1999 Sep; 1(1):47-53.
Score: 0.137
-
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep; 134(3):478-85.
Score: 0.096
-
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):387-93.
Score: 0.057